Chapter 26, Ep 1 of 5: Chronic Pancreatitis Framework and Pain

Episode one of the Chronic Pancreatitis, Cysts, and Neoplasms chapter builds the framework from a single fact: fewer than three percent of heavy drinkers ever develop the disease, so exposure alone is never enough and a co-modifier has to do the converting. The organizing idea is that tobacco and a genetic background decide who progresses, and where each gene sits in the trypsin-control pathway sets its inheritance, penetrance, and cancer risk. Diagnosis is calibrated to stage, CT for calcification, secretin-MRCP for the duct, endoscopic ultrasound for minimal-change parenchyma, and function testing for the gland that still looks normal. Pain is worked in steps, from cessation and non-opioid analgesics through neuromodulators to decompression, with the randomized shift that moved early surgery ahead of endoscopy the tested pivot. Cause, mechanism, staging, and steps throughout.   Topics covered Fibroinflammatory disease and the co-modifier concept Tobacco and genetic background as converters TIGAR-O etiologic classification Genetic forms and trypsin regulation Cationic trypsinogen cancer risk and surveillance Staged diagnosis: CT, secretin-MRCP, endoscopic ultrasound Functional testing for early disease Stepwise pain management Early surgery in dilated-duct disease     Key decisions Fewer than three percent of heavy alcohol users develop chronic pancreatitis, so a toxic exposure needs a co-modifier, usually tobacco plus a genetic background, before fibrosis takes hold. A patient over fifty with a first idiopathic acute pancreatitis episode needs cross-sectional imaging follow-up once inflammation settles, because obstruction from pancreatic adenocarcinoma is the must-not-miss of the obstructive category. Cationic trypsinogen gain-of-function disease carries the highest cancer risk of any subset, earning routine surveillance with annual MRI alternating with endoscopic ultrasound starting at age forty. Genetic testing is indicated when the cause is unclear, when there is a family history, or when onset is under about thirty-five. Work up diagnosis as CT first for calcification, secretin-enhanced MRCP next for duct and side branches, endoscopic ultrasound for minimal-change parenchyma, and secretin-stimulated function testing when structure still looks normal, with a peak duodenal bicarbonate at or above eighty milliequivalents per liter carrying high negative predictive value. Manage pain in steps starting with alcohol and tobacco cessation, then non-opioid analgesics, neuromodulators such as gabapentin or pregabalin, and enzyme replacement when exocrine insufficiency coexists, with narcotics minimized. In painful chronic pancreatitis with a dilated main duct, early surgical drainage beats the endoscopy-first approach, so surgery is now the early move rather than the salvage move.     This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.   For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.   Questions or feedback: [email protected].